Annals of Surgical Oncology

, Volume 13, Issue 8, pp 1047–1053 | Cite as

A Pathologic Complete Response of Rectal Cancer to Preoperative Combined-Modality Therapy Results in Improved Oncological Outcome Compared With Those Who Achieve No Downstaging on the Basis of Preoperative Endorectal Ultrasonography

  • Francesco Stipa
  • David B. Chessin
  • Jinru Shia
  • Philip B. Paty
  • Martin Weiser
  • Larissa K. F. Temple
  • Bruce D. Minsky
  • W. Douglas Wong
  • Jose G. GuillemEmail author



Preoperative combined-modality therapy (CMT) is the preferred treatment for locally advanced rectal cancer (endorectal ultrasonography [ERUS] T3–4, N1, or clinically bulky) and achieves a pathologic complete response (pCR) in 4% to 33% of patients. However, the prognostic significance of pCR remains unclear.


A prospectively collected database was queried to identify 200 patients with locally advanced disease treated from 1992 to 2002. The pCR group was defined as having no evidence of viable tumor on pathologic analysis. The no-downstaging group was defined as no difference between the pre-CMT ERUS stage and the pathologic stage. Those achieving some downstaging but not pCR were excluded. Patients were treated with CMT (5040 cGy of radiation and 5-fluorouracil–based chemotherapy) followed by surgery, and 51 (85%) in the pCR group and 129 (92%) in the no-downstaging group (P = .1) received postoperative chemotherapy. Recurrence-free survival (RFS) and overall survival (OS) were determined by using the Kaplan-Meier method.


The median follow-up was 38.6 months (range, 18.2–124.9 months). The pCR (n = 60) and control (n = 140) groups were similar in age (P = .6), sex (P = .4), distance of the tumor from the anal verge (P = .3), pre-CMT ERUS stage (P = .2), and comorbidities (P = .2). The 5-year RFS was 96% and 54% in the pCR and control groups, respectively (P < .00001); the 5-year OS was 90% and 68% (P = .009). Sphincter-preservation rates were higher in the pCR group (P = .01).


Rectal cancer patients with pCR after preoperative CMT have improved RFS, OS, and sphincter preservation compared with patients without downstaging. Because pCR seems to be associated with better outcome, an understanding of the factors governing the response to CMT should be pursued.


Rectal cancer Radiotherapy Pathologic response Combined modality therapy Oncologic outcome 



Supported by National Institutes of Health grant RO1 82534-01 (J.G.G.).


  1. 1.
    Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351:1731–40PubMedCrossRefGoogle Scholar
  2. 2.
    Ahmad NR, Nagle D. Long-term results of preoperative radiation therapy alone for stage T3 and T4 rectal cancer. Br J Surg 1997; 84:1445–8PubMedCrossRefGoogle Scholar
  3. 3.
    Mehta VK, Poen J, Ford J, et al. Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer. Dis Colon Rectum 2001; 44:52–8PubMedCrossRefGoogle Scholar
  4. 4.
    Guillem JG, Chessin DB, Cohen AM, et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg 2005; 241:829–36PubMedCrossRefGoogle Scholar
  5. 5.
    Garcia-Aguilar J, Hernandez de Anda E, Sirivongs P, Lee SH, Madoff RD, Rothenberger DA. A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum 2003; 46:298–304PubMedCrossRefGoogle Scholar
  6. 6.
    Janjan NA, Abbruzzese J, Pazdur R, et al. Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. Radiother Oncol 1999; 51:153–60PubMedCrossRefGoogle Scholar
  7. 7.
    Onaitis MW, Noone RBF, R., Hurwitz H, et al. Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival. Ann Surg Oncol 2001; 8:801–6.PubMedGoogle Scholar
  8. 8.
    Theodoropoulos G, Wise WE, Padmanabhan A, et al. T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum 2002; 45:895–903PubMedCrossRefGoogle Scholar
  9. 9.
    Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004; 240:711–7; discussion 717–8PubMedGoogle Scholar
  10. 10.
    Hildebrandt U, Feifel G, Schwarz HP, Scherr O. Endorectal ultrasound: instrumentation and clinical aspects. Int J Colorectal Dis 1986; 1:203–7PubMedCrossRefGoogle Scholar
  11. 11.
    Beynon J, Roe AM, Foy DM, Channer JL, Virjee J, Mortensen NJ. Preoperative staging of local invasion in rectal cancer using endoluminal ultrasound. J R Soc Med 1987; 80:23–4PubMedGoogle Scholar
  12. 12.
    Skibber J, Hoff PM, Minsky BD. Cancer of the Rectum. Philadelphia: Lippincott Williams & Wilkins, 2001Google Scholar
  13. 13.
    Heald RJ, Moran BJ, Ryall RD, Sexton R, MacFarlane JK. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997. Arch Surg 1998; 133:894–9PubMedCrossRefGoogle Scholar
  14. 14.
    Enker WE, Thaler HT, Cranor ML, Polyak T. Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg 1995; 181:335–46PubMedGoogle Scholar
  15. 15.
    AJCC Cancer Staging Manual. 5th ed. Philadelphia: Lippincott-Raven, 1998Google Scholar
  16. 16.
    Ruo L, Tickoo S, Klimstra DS, et al. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg 2002; 236:75–81PubMedCrossRefGoogle Scholar
  17. 17.
    Guillem JG, Puig-La Calle J Jr, Akhurst T, et al. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum 2000; 43:18–24PubMedCrossRefGoogle Scholar
  18. 18.
    Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905–14PubMedCrossRefGoogle Scholar
  19. 19.
    Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343–51PubMedCrossRefGoogle Scholar
  20. 20.
    Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337–45PubMedCrossRefGoogle Scholar
  21. 21.
    Starling N, Cunningham D. Monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor in advanced colorectal cancers: present and future directions. Curr Opin Oncol 2004; 16:385–90PubMedCrossRefGoogle Scholar
  22. 22.
    Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335–42PubMedCrossRefGoogle Scholar
  23. 23.
    Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10:145–7PubMedCrossRefGoogle Scholar
  24. 24.
    Moore HG, Gittleman AE, Minsky BD, et al. Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum 2004; 47:279–86PubMedCrossRefGoogle Scholar
  25. 25.
    Moore HG, Shia J, Klimstra DS, et al. Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome. Ann Surg Oncol 2004; 11:955–61PubMedCrossRefGoogle Scholar
  26. 26.
    Zirbes TK, Baldus SE, Moenig SP, et al. Prognostic impact of p21/waf1/cip1 in colorectal cancer. Int J Cancer 2000; 89:14–8PubMedCrossRefGoogle Scholar
  27. 27.
    Buglioni S, D’Agnano I, Cosimelli M, et al. Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: independent prognostic role of p53 and bcl-2. Int J Cancer 1999; 84:545–52PubMedCrossRefGoogle Scholar
  28. 28.
    Maeda K, Chung Y, Kang S, et al. Cyclin D1 overexpression and prognosis in colorectal adenocarcinoma. Oncology 1998; 55:145–51PubMedCrossRefGoogle Scholar
  29. 29.
    Petrowsky H, Sturm I, Graubitz O, et al. Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases. Eur J Surg Oncol 2001; 27:80–7PubMedCrossRefGoogle Scholar
  30. 30.
    Jung C, Motwani M, Kortmansky J, et al. The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells. Clin Cancer Res 2003; 9(16 Pt 1):6052–61PubMedGoogle Scholar
  31. 31.
    Schwartz GK, O’Reilly E, Ilson D, et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 2002; 20:2157–70PubMedCrossRefGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 2006

Authors and Affiliations

  • Francesco Stipa
    • 1
  • David B. Chessin
    • 1
  • Jinru Shia
    • 2
  • Philip B. Paty
    • 1
  • Martin Weiser
    • 1
  • Larissa K. F. Temple
    • 1
  • Bruce D. Minsky
    • 3
  • W. Douglas Wong
    • 1
  • Jose G. Guillem
    • 1
    Email author
  1. 1.Department of Surgery-Colorectal ServiceMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Department of PathologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  3. 3.Department of Radiation OncologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations